This guest post is from the BiotechBlog Intern, Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin […]
Thinking Laterally: Examining the Flexible Career Path in Life Sciences Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
A brave new Europe with the introduction of the EU Clinical Trials Directive: Impact upon the pharma industry and academic research with special emphasis on…
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Intellectual property: The driving force for growth and funding
Go to paperABSTRACT: For most ‘bio-entrepreneurs’ the science is the easy part — leveragin…
Intellectual property: The driving force for growth and funding Read Post »
Made available by the elective open access option at the Journal of Commercial Biotechnology, this paper is free to view without subscription: The
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Fostering the process of adoption of personalised medicine: A matter of communication or a matter of cost?
Go to paperABSTRACT: Pharmacogenetics, along with…
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
Biotechnology in Countries Starting with "I" – Part 4: Ireland Read Post »
This guest post is from the BiotechBlog Intern, Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin
Crowdsourcing in the Biotech world: Innovation and outreach to a wider public Read Post »
In the last weeks, India has seen serious setbacks to its life sciences industry. The NIH recently announced that they
I am off to Taiwan for the “Asian Food and Agribusiness Conference 2013” and then a brief stopover in Korea.
Five years ago I built a biotechnology innovation index and I have been using it since tracking global biotechnology innovation